Currently, the most extensively studied ICIs in MM clinical trials include programmed cell death protein-1 (PD-1) antibody and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody (24–26). The gene discussed is PDCD1; the disease is Miyoshi myopathy.